Neoadjuvant chemotherapy for colon cancer based on evidence-based medicine.
- Author:
Xiaodong YANG
1
;
Yi LIU
Author Information
1. Department of General Sugery, The First Affiliated Hospital of Anhui Medical University, Hefei 230061, China. yiliu@medmail.com.cn.
- Publication Type:Journal Article
- MeSH:
Colonic Neoplasms;
drug therapy;
therapy;
Evidence-Based Medicine;
Fluorouracil;
Humans;
Neoadjuvant Therapy
- From:
Chinese Journal of Gastrointestinal Surgery
2014;17(11):1151-1155
- CountryChina
- Language:Chinese
-
Abstract:
The incidence of colon cancer has been increasing in recent years with the improvement in living standard, and becomes one of the leading causes of cancer-related death. While radical surgery remains the primary choice for colon cancer, neoadjuvant chemotherapy has significantly improved the successful rate of surgery and increased postoperative survival. In addition to traditional chemotherapy with 5-Fu or oxliplatin, molecular targeted drugs lead to a higher response rate and show its dramatic effect on disease-recurrence time. However some side effects such as disease progression during chemotherapy, bleeding or liver toxicity should be concerned. In addition, indications for neoadjuvant chemotherapy do not reach a consensus. In the future, these controversies may be solved based on some large randomized controlled trials.
